Genemen Biotech

Genemen Biotech (Suzhou Genemen Biotech Co., Ltd.) is a Chinese biotechnology company specializing in the development and manufacturing of recombinant protein drugs and biosimilars. Founded in 2010 and headquartered in Suzhou, the company was acquired by Shenzhen Salubris Pharmaceuticals in 2014 to serve as its primary biological drug R&D and production platform. Genemen's portfolio focuses on therapeutic areas such as autoimmune diseases, metabolic disorders, and bone health, with key products including an etanercept biosimilar, a recombinant GLP-1 receptor agonist (SAL015), and teriparatide. The company operates state-of-the-art GMP-compliant manufacturing facilities in Taicang, capable of large-scale eukaryotic protein production and lyophilization. As a core subsidiary of the Salubris group, Genemen Biotech is instrumental in the parent company's strategic expansion into the high-growth biologics market.